摘要
目的观察博来霉素、顺铂治疗恶性胸腔积液的疗效。方法76例肺癌伴恶性胸腔积液患者随机分为2组，一组予胸腔注射博来霉素40～60mg／次、另一组予胸腔注射顺铂60～80mg／次，共2—3次，每次间隔1周。结果博来霉素组、顺铂组治疗总有效率分别为92．1％和89，5％。顺铂组1例患者出现骨髓抑制，其余毒副反应与博来霉素组相比无显著差异。结论两组药物对恶性胸腔积液均有良好疗效，顺铂由于价格优势，适用于广泛的患者群，但有骨髓抑制的患者慎用。
Objective To evaluate the efficacy and safety of bleomycin and cis-diaminodichloroplatin on the patients of lung cancer with malignant pleural effusion. Methods 76 individuals were divided into two groups, each patient was injected by thorax respectively, bleomycin 40 - 60mg, cis-diaminodichloroplatin 60 - 80mg, Observed the toxic response. Results After treatment the total efficiency in bleomycin and cis-diaminodichloroplatin were 92.1% and 89.5% respectively（ P 〉 0.05 ）. Little obvious side effects was found in two groups, only 1 patient in cis-diaminodichlorplatin found inhibition of myeloid. Conclusion bleomycin and cis-diaminodichloroplatin were efficient and safety on patients with lung cancer with malignant, but cis-diaminodichloroplatin is more cheaper.
出处
《四川医学》
CAS
2008年第4期413-414,共2页
Sichuan Medical Journal
关键词
肺癌
胸腔内药物治疗
恶性胸腔积液
lung cancer
drug injected in thorax
malignant pleural effusion
